Pharmacogenetic analysis of CYP2C19 in Colombian ACS patients treated with clopidogrel revealed that 13.5% experienced adverse drug reactions, of which 25% carried at least one polymorphic allele.
Observational (n=166)
What are the allele frequencies of CYP2C19 variants and their association with adverse drug reactions in Colombian patients with acute coronary syndrome treated with clopidogrel?
The study identifies new potentially pathogenic mutations and regulatory variants in CYP2C19 that may influence clopidogrel response and bleeding risk in Colombian patients with ACS.
Clopidogrel, an oral platelet P2Y12 receptor blocker, is used in the treatment of acute coronary syndrome. Interindividual variability in treatment response and the occurrence of adverse effects has been attributed to genetic variants in CYP2C19. The analysis of relevant pharmacogenes in ethnically heterogeneous and poorly studied populations contributes to the implementation of personalized medicine. We analyzed the coding and regulatory regions of CYP2C19 in 166 patients with acute coronary syndrome (ACS) treated with clopidogrel. The allele frequencies of CYP2C19 alleles *1, *2, *4, *17, *27 and *33 alleles were 86.1%, 7.2%, 0.3%, 10.2%, 0.3% and 0.3%, respectively. A new potentially pathogenic mutation (p.L15H) and five intronic variants with potential splicing effects were detected. In 14.4% of the patients, a new haplotype in strong linkage disequilibrium was identified. The clinical outcome indicated that 13.5% of the patients presented adverse drugs reactions with a predominance of bleeding while 25% of these patients were carriers of at least one polymorphic allele. We propose that new regulatory single-nucleotide variants (SNVs) might potentially influence the response to clopidogrel in Colombian individuals.
Angulo-Aguado et al. (Tue,) conducted a observational in Acute coronary syndrome (n=166). Clopidogrel was evaluated on Adverse drug reactions (predominantly bleeding). Pharmacogenetic analysis of CYP2C19 in Colombian ACS patients treated with clopidogrel revealed that 13.5% experienced adverse drug reactions, of which 25% carried at least one polymorphic allele.